BR9908796A - Uso de compostos de macrolìdeo, método de tratamento e prevenção de ards, composição farmacêutica e composto macrolìdeo - Google Patents

Uso de compostos de macrolìdeo, método de tratamento e prevenção de ards, composição farmacêutica e composto macrolìdeo

Info

Publication number
BR9908796A
BR9908796A BR9908796-0A BR9908796A BR9908796A BR 9908796 A BR9908796 A BR 9908796A BR 9908796 A BR9908796 A BR 9908796A BR 9908796 A BR9908796 A BR 9908796A
Authority
BR
Brazil
Prior art keywords
macrolide
prevention
treatment
ards
compounds
Prior art date
Application number
BR9908796-0A
Other languages
English (en)
Inventor
Tadatsura Koshika
Itsuo Nagatomi
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of BR9908796A publication Critical patent/BR9908796A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"USO DE COMPOSTOS DE MACROLìDEO, MéTODO DE TRATAMENTO E PREVENçãO DE ARDS, COMPOSIçãO FARMACêUTICA E COMPOSTO MACROLìDEO". Compostos de macrolídeo, tais como a Substância FK506 e seus compostos relativos, são providos para a prevenção ou tratamento de síndrome de angústia respiratória adulta. A composição contendo ditos compostos é também descrita.
BR9908796-0A 1998-03-06 1999-03-04 Uso de compostos de macrolìdeo, método de tratamento e prevenção de ards, composição farmacêutica e composto macrolìdeo BR9908796A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP2231A AUPP223198A0 (en) 1998-03-06 1998-03-06 New use
PCT/JP1999/001064 WO1999044597A2 (en) 1998-03-06 1999-03-04 Use of macrolide compounds for the treatment of ards

Publications (1)

Publication Number Publication Date
BR9908796A true BR9908796A (pt) 2000-10-31

Family

ID=3806495

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908796-0A BR9908796A (pt) 1998-03-06 1999-03-04 Uso de compostos de macrolìdeo, método de tratamento e prevenção de ards, composição farmacêutica e composto macrolìdeo

Country Status (15)

Country Link
US (1) US6333334B1 (pt)
EP (1) EP1059921B1 (pt)
JP (1) JP3367105B2 (pt)
KR (1) KR100395571B1 (pt)
CN (1) CN1133429C (pt)
AT (1) ATE244008T1 (pt)
AU (1) AUPP223198A0 (pt)
BR (1) BR9908796A (pt)
CA (1) CA2322027C (pt)
DE (1) DE69909257T2 (pt)
DK (1) DK1059921T3 (pt)
ES (1) ES2196840T3 (pt)
HK (1) HK1036406A1 (pt)
PT (1) PT1059921E (pt)
WO (1) WO1999044597A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
PL2071917T3 (pl) * 2006-09-29 2013-04-30 Infa Sa System opakowaniowy dla kompozycji farmaceutycznych oraz zestaw do podawania dożylnego
KR20090094090A (ko) * 2006-12-28 2009-09-03 리머릭 바이오파르마 인코오포레이티드 치료를 위한 방법 및 조성물
WO2008127746A1 (en) 2007-01-10 2008-10-23 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
CN101011414B (zh) * 2007-01-29 2010-07-21 褚福明 一种肺脑合剂药物
US7947733B2 (en) * 2007-07-31 2011-05-24 Limerick Biopharma Phosphorylated pyrone analogs and methods
CN101810633B (zh) * 2010-03-31 2011-12-14 湖北丝宝药业有限公司 地红霉素在制备治疗慢性非感染性呼吸道疾病药物的用途
GB201212773D0 (en) * 2012-07-18 2012-08-29 Ucl Business Plc Vascular remodelling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB2248184A (en) * 1990-09-28 1992-04-01 Fujisawa Pharmaceutical Co New use of macrolide compounds for active oxygen-mediated diseases
IE65341B1 (en) * 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
GB9218027D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
US5290689A (en) * 1992-09-28 1994-03-01 Merck & Co., Inc. New cyclic FR-900520 microbial biotransformation agent

Also Published As

Publication number Publication date
ATE244008T1 (de) 2003-07-15
KR20010041046A (ko) 2001-05-15
HK1036406A1 (en) 2002-01-04
DE69909257D1 (de) 2003-08-07
CN1292695A (zh) 2001-04-25
EP1059921B1 (en) 2003-07-02
ES2196840T3 (es) 2003-12-16
WO1999044597A2 (en) 1999-09-10
EP1059921A2 (en) 2000-12-20
PT1059921E (pt) 2003-11-28
US6333334B1 (en) 2001-12-25
CA2322027A1 (en) 1999-09-10
AUPP223198A0 (en) 1998-04-02
JP2001520682A (ja) 2001-10-30
CA2322027C (en) 2009-05-12
JP3367105B2 (ja) 2003-01-14
DK1059921T3 (da) 2003-10-27
CN1133429C (zh) 2004-01-07
DE69909257T2 (de) 2004-02-19
WO1999044597A3 (en) 1999-12-29
KR100395571B1 (ko) 2003-08-21

Similar Documents

Publication Publication Date Title
TR200101412T2 (tr) Yeni bileşikler.
NO20006630D0 (no) Farmasöytisk sammensetning for behandlingen av diabetes
DE19875032I2 (de) Mometason-Furoate-Monohydrat, Verfahren zu seiner Herstellung und das enthaltende pharmazeutische Zusammensetzungen
NO973479L (no) Substituerte heterosykliske forbindelser, fremgangsmåte for fremstilling og farmasöytiske blandinger inneholdende samme
DK0915898T3 (da) Krystalform I af clarithromycin
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
PL306084A1 (en) Novel compound and method of obtaining them as well as pharmaceutic agent containing such compounds
EE200200208A (et) Oligosahhariidid, nende valmistamismeetod ja kasutamine ning farmatseutilised kompositsioonid
HK1031869A1 (en) 1-Ä(1-Substituted-4-piperidinyl)methylÜ-4-piperdine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds.
ATE300541T1 (de) Pyrazolopyridinderivate
BR9709654A (pt) Derivados da tiazolidina-2,4-diona substituídos seus processos de obtenção e as composições farmacêuticas que os contêm
ATE180781T1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
DE69729183D1 (de) Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen
BR9908796A (pt) Uso de compostos de macrolìdeo, método de tratamento e prevenção de ards, composição farmacêutica e composto macrolìdeo
BR9908427A (pt) Composições farmacêuticas e uso das mesmas
DK1124841T3 (da) Substituerede phenylalkenoylguanidiner, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler eller diagnosemidler og lægemidler, som indeholder dem
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
EE03611B1 (et) Taksoidid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
EE04914B1 (et) Eletriptaanvesinikbromiidi monohüdraat, selle kasutamine ja protsess selle valmistamiseks ning eletriptaanvesinikbromiidi monohüdraati sisaldav farmatseutiline kompositsioon
ATE237614T1 (de) Benzo(c)chinolizin derivate,deren herstellung und verwendung als 5-alfa-reduktase inhibitoren
NO882030D0 (no) Fremgangsmaate til fremstilling av hydrasinderivater til bruk som antihypertensivt middel.
WO2000074665A3 (en) New use of macrolide compounds for inducing chondrogenic differentiation
ATE397615T1 (de) 6-o-alkyl-2-nor-2-substituierte ketolidderivate
NZ505085A (en) Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi
ATE204847T1 (de) Tetracyclische aromatische retinoide verbindungen,ihre herstellung und verwendung

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP)

Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO., LTD.

B25D Requested change of name of applicant approved

Owner name: ASTELLAS PHARMA INC. (JP)

Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADO DE INT.CI: A61K 31/436; C07D 498/18; A61P 11/00; A61P 43/00

Ipc: A61K 31/436 (2008.01), C07D 498/18 (2008.01), A61P

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]